Clinical Trial Detail

NCT ID NCT03602079
Title Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Klus Pharma Inc.
Indications

stomach cancer

breast cancer

Advanced Solid Tumor

Therapies

A166

Age Groups: adult senior

Additional content available in CKB BOOST